The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of disease who have confirmed presence of amyloid pathology.
Eisai and Biogen have said they have already submitted a supplemental filing to the FDA to upgrade that to a full, non-conditional approval.
